A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion

Trial Profile

A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Retinal oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms COPERNICUS
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2015 According to a Regeneron Pharmaceuticals media release, aflibercept has been recommended for approval by the European CHMP for the treatment of visual impairment due to macular oedema secondary to central or branch retinal vein occlusion.
    • 12 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top